Abstract
L-arginine is a conditionally essential amino acid, which is the cellular regulator of many vital functions of the body. He is involved in the regulation of the tone of the smooth muscle component of the blood vessels wall, bronchi, and intestines. L-arginine is a substrate for the nitric oxide synthase (NOS), which produces nitric oxide (NO). NO, produced in the vascular endothelium of endothelial NOS, is responsible for the relaxation of smooth muscles and is necessary
to lower blood pressure. L-arginine has a high functional priority in the production of NO and, therefore, in the physiology of the cardiovascular and cerebrovascular systems. L-arginine can reduce obesity, lower blood pressure, suppress oxidative processes and normalize endothelial dysfunction, contributing to remission in type 2 diabetes. Larginine is also used by cells of the immune system, can reduce the level of infection, especially in case of impaired immune function. L-arginine slows down aging, inhibits platelet aggregation, and regulates multiple metabolic pathways associated with the metabolism of fatty acids, glucose, amino acids and proteins. Therefore, one should take into account the great therapeutic potential of L-arginine and continue to study the possibilities of its use as a promising drug against the progression of vascular dysfunction associated with aging, diabetes and cardiovascular diseases.
References
2. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009;157(6):922-30.
3. Morris SM Jr. Arginine metabolism revisited. J Nutr. 2016;146(12):2579S-86S.
4. Heffernan KS, Fahs CA, Ranadive SM, Patvardhan EA. L-arginine as a nutritional prophylaxis against vascular endothelial dysfunction with aging. J Cardiovasc Pharmacol Ther. 2010;15(1):17-23.
5. McRae MP. Therapeutic benefits of l-Arginine: an umbrella review of meta-analyses. J Chiropr Med. 2016;15(3):184-9.
6. Krause M, Rodrigues-Krause J, O’Hagan C, De Vito G, Boreham C, Susta D, et al. Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metabolism. 2012;61(11):1528-37.
7. Rodrigues-Krause J, Krause M, Rocha IMGD, Umpierre D, Fayh APT. Association of l-Arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders: a systematic review and meta-analysis. Nutrients. 2018;11(1):E15.
8. Michael SK, Surks HK, Wang Y. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A. 2008; 105(8):6702–7.
9. Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15(5):292-316.
10. Марков ХМ. Молекулярные механизмы дисфункции сосудистого эндотелия. Кардиология. 2005;6:87-95. (Markov KhM. Molecular mechanisms of vascular endothelial dysfunction. Kardiologiya. 2005;6:87-95).
11. Chen M, Yi B, Zhu N, Wei X, Zhang GX, Huang S, et al. Pim1 kinase promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser633. Cardiovasc Res. 2016;109:141-50.
12. Bibli SI, Zhou Z, Zukunft S, Fisslthaler B, Andreadou I, Szabo C, et al. Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischaemic insult: role of PYK2. Cardiovasc Res. 2017;113:926-37.
13. Heffernan KS, Vieira VJ, Valentine RJ. Microvascular function and ageing L-arginine, tetrahydrobiopterin and the search for the fountain of vascular youth. J Physiol. 2008;586(8):2041-2.
14. Delp MD, Behnke BJ, Spier SA, Wu G, Muller-Delp JM. Ageing diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles. J Physiol. 2008;586(4):1161-8.
15. Durante W, Johnson FK, Johnson RA. Аrginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34(9): 906-11.